DE60026532D1 - Screening-methode für inhibitoren von acrab und acrab-ähnlichen ausfluss-pumpen - Google Patents

Screening-methode für inhibitoren von acrab und acrab-ähnlichen ausfluss-pumpen

Info

Publication number
DE60026532D1
DE60026532D1 DE60026532T DE60026532T DE60026532D1 DE 60026532 D1 DE60026532 D1 DE 60026532D1 DE 60026532 T DE60026532 T DE 60026532T DE 60026532 T DE60026532 T DE 60026532T DE 60026532 D1 DE60026532 D1 DE 60026532D1
Authority
DE
Germany
Prior art keywords
acrab
inhibitors
screening method
outflow pumps
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60026532T
Other languages
English (en)
Inventor
Margret Oethinger
Stuart B Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRUSTEES OF TUFTS COLLEGE MEDF
Tufts University
Original Assignee
TRUSTEES OF TUFTS COLLEGE MEDF
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRUSTEES OF TUFTS COLLEGE MEDF, Tufts University filed Critical TRUSTEES OF TUFTS COLLEGE MEDF
Application granted granted Critical
Publication of DE60026532D1 publication Critical patent/DE60026532D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60026532T 1999-07-22 2000-07-21 Screening-methode für inhibitoren von acrab und acrab-ähnlichen ausfluss-pumpen Expired - Lifetime DE60026532D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/358,948 US6346391B1 (en) 1999-07-22 1999-07-22 Methods of reducing microbial resistance to drugs
PCT/US2000/020014 WO2001007030A2 (en) 1999-07-22 2000-07-21 Compositions an inhibitor of an accrab-like efflux pump for reducung microbial resistance to drugs

Publications (1)

Publication Number Publication Date
DE60026532D1 true DE60026532D1 (de) 2006-05-04

Family

ID=23411689

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60026532T Expired - Lifetime DE60026532D1 (de) 1999-07-22 2000-07-21 Screening-methode für inhibitoren von acrab und acrab-ähnlichen ausfluss-pumpen

Country Status (8)

Country Link
US (6) US6346391B1 (de)
EP (2) EP1276503B1 (de)
JP (2) JP2003523317A (de)
AT (1) ATE319478T1 (de)
AU (1) AU783818B2 (de)
CA (2) CA2718926A1 (de)
DE (1) DE60026532D1 (de)
WO (1) WO2001007030A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CO5370679A1 (es) 1999-06-01 2004-02-27 Smithkline Beecham Corp Inhibidores fab 1
US6346391B1 (en) * 1999-07-22 2002-02-12 Trustees Of Tufts College Methods of reducing microbial resistance to drugs
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
NZ517706A (en) 1999-10-08 2004-01-30 Affinium Pharm Inc Fab I inhibitors
US6656703B1 (en) * 1999-12-29 2003-12-02 Millennium Pharamaceuticals, Inc. High throughput screen for inhibitors of fatty acid biosynthesis in bacteria
ES2320984T3 (es) * 2001-04-06 2009-06-01 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
WO2003056294A2 (en) * 2001-07-13 2003-07-10 Paratek Pharmaceuticals, Inc. Methods for identifying and using marr family polypeptide binding compounds
US20060084678A1 (en) * 2001-07-13 2006-04-20 Paratek Pharmaceuticals, Inc. Methods for identifying and using MarR family polypeptide binding compounds
WO2003006626A2 (en) * 2001-07-13 2003-01-23 Trustees Of Tufts College CRYSTAL STRUCTURE OF A MarR FAMILY POLYPEPTIDE
US7691403B2 (en) * 2001-11-21 2010-04-06 Kimberly-Clark Worldwide, Inc. Non-absorbent tampon containing additives inhibiting TSST-1
US7118759B2 (en) * 2001-11-21 2006-10-10 Kimberly-Clark Worldwide, Inc. Absorbent articles containing additives
US20030158156A1 (en) * 2001-11-21 2003-08-21 Kimberly-Clark Worldwide, Inc. Methods for inhibiting the production of TSST-1
US20050255538A1 (en) * 2002-03-15 2005-11-17 Buxser Stephen E Methods for screening for AcrAB efflux pump inhibitors
CA2508792C (en) * 2002-12-06 2013-02-05 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
US7829543B2 (en) * 2003-01-07 2010-11-09 Paratek Pharmaceuticals, Inc. Substituted polyamines as inhibitors of bacterial efflux pumps
JP4880448B2 (ja) 2003-03-17 2012-02-22 アフィナム ファーマシューティカルズ，インコーポレーテッド 複数の抗生物質を含む組成物、及びそれを用いる方法
US20050192240A1 (en) * 2004-01-09 2005-09-01 Yun-Liang Yang Methods and compositions relating to expression factors
JP2008500965A (ja) * 2004-03-17 2008-01-17 エムペックス・ファーマシューティカルズ・インコーポレーテッド 細菌の排出ポンプ阻害剤の使用および投与
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
ES2515101T3 (es) * 2004-06-04 2014-10-29 Debiopharm International Sa Derivados de acrilamida como agentes antibióticos
GB0511203D0 (en) * 2005-06-02 2005-07-06 Univ Birmingham Vaccines
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
US8343536B2 (en) 2007-01-25 2013-01-01 Cook Biotech Incorporated Biofilm-inhibiting medical products
EP2125802A4 (de) * 2007-02-16 2014-08-20 Debiopharm Int Sa Salze, prodrugs und polymorphe von fab-i-inhibitoren
US20100130439A1 (en) * 2007-04-26 2010-05-27 Romesberg Floyd E Genomic mutation inhibitors that inhibit y family dna polymerases
FR2970964B1 (fr) 2011-01-28 2013-12-13 Univ Claude Bernard Lyon Nouveaux derives d'azacoumarines presentant une activite inhibitrice des pompes mdr
SI2861608T1 (sl) 2012-06-19 2019-08-30 Debiopharm International Sa Derivati predzdravila (E)-N-metil-N-((3-metilbenzofuran-2-IL)metil)- 3-(7-okso-5,6,7,8-tetrahidro-1 ,8-nafthiridin-3-il)akrilamid
US9532986B2 (en) * 2014-04-08 2017-01-03 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
CN110417797B (zh) * 2015-04-02 2021-07-30 创新先进技术有限公司 认证用户的方法及装置
EP3394261A4 (de) * 2015-12-23 2019-11-27 Oregon State University Antibakterielle antisense-verbindungen und verfahren
CA3014541A1 (en) 2016-02-26 2017-08-31 Debiopharm International S.A. Medicament for treatment of diabetic foot infections
GB201615693D0 (en) 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589470A (en) 1990-02-26 1996-12-31 Trustees Of Tufts College Reducing tetracycline resistance in living cells
US5064821A (en) 1982-11-18 1991-11-12 Trustees Of Tufts College Method and compositions for overcoming tetracycline resistance within living cells
US4806529A (en) 1982-11-18 1989-02-21 Trustees Of Tufts College, Tufts University Tetracycline activity enhancement
FR2655545B1 (fr) 1989-12-11 1994-06-10 Rhone Poulenc Sante Nouvelle application therapeutique des derives des fluoroquinolones.
TW318189B (de) 1991-12-06 1997-10-21 American Cyanamid Co
WO1994005810A1 (en) 1992-08-28 1994-03-17 Trustees Of Tufts College Multiple antibiotic resistance operon assays
JPH10513048A (ja) 1995-01-23 1998-12-15 マイクロサイド・ファーマシューティカルズ・インコーポレーテッド 生体分子の変調剤のためのスクリーニング
US5989832A (en) * 1995-04-21 1999-11-23 Microcide Pharmaceuticals, Inc. Method for screening for non-tetracycline efflux pump inhibitors
WO1999032657A1 (en) 1997-12-23 1999-07-01 Microcide Pharmaceuticals, Inc. Staphylococcus aureus histidine protein kinase essential genes
WO1999017607A2 (en) * 1997-10-02 1999-04-15 Trustees Of Tufts College Methods and compositions for reducing bacterial tolerance of disinfectants and organic solvents
AU9785698A (en) 1997-10-02 1999-04-27 Microcide Pharmaceuticals, Inc. Fungal efflux pump inhibitors
US6068972A (en) 1997-10-03 2000-05-30 Trustees Of Tufts College Methods and compositions for reducing bacterial tolerance to antibacterials, disinfectants and organic solvents
US20040024068A1 (en) * 1998-01-23 2004-02-05 Trustees Of Tufts College Antimicrobial compounds
AU2337599A (en) 1998-01-23 1999-08-09 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
AU2332499A (en) 1998-01-23 1999-08-09 Trustees Of Tufts College Antimicrobial compounds
US6410041B1 (en) * 1998-04-28 2002-06-25 Trustees Of Tufts College Culturing cells in presence of amphipathic weak bases and/or cations and multiple drug resistance inhibitor containing reserpine
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
AU757777B2 (en) 1998-12-04 2003-03-06 Influx, Inc. Inhibitors of multidrug transporters
US6346391B1 (en) * 1999-07-22 2002-02-12 Trustees Of Tufts College Methods of reducing microbial resistance to drugs
US20050255538A1 (en) * 2002-03-15 2005-11-17 Buxser Stephen E Methods for screening for AcrAB efflux pump inhibitors

Also Published As

Publication number Publication date
ATE319478T1 (de) 2006-03-15
AU783818B2 (en) 2005-12-08
CA2378883C (en) 2011-01-11
WO2001007030A3 (en) 2002-11-14
US8012711B2 (en) 2011-09-06
US6677133B2 (en) 2004-01-13
AU6366600A (en) 2001-02-13
US7026136B2 (en) 2006-04-11
WO2001007030A2 (en) 2001-02-01
CA2378883A1 (en) 2001-02-01
EP1276503A2 (de) 2003-01-22
US20020132814A1 (en) 2002-09-19
EP1674112A1 (de) 2006-06-28
JP2003523317A (ja) 2003-08-05
US20050261165A1 (en) 2005-11-24
EP1276503B1 (de) 2006-03-08
CA2718926A1 (en) 2001-02-01
US20090298873A1 (en) 2009-12-03
US6346391B1 (en) 2002-02-12
US20060264517A1 (en) 2006-11-23
JP2011137028A (ja) 2011-07-14
US20110301127A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
ATE319478T1 (de) Screening-methode für inhibitoren von acrab und acrab-ähnlichen ausfluss-pumpen
ECSP085181A (es) Sistema de administración de fármacos que comprende rapamicina y derivados de la misma para la prevención y tratamiento de enfermedades vasculares
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
PE20001112A1 (es) Derivados de quinolina como agentes antibacterianos
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
BRPI0508451A (pt) método de tratamento de linfoma não-hodgkin em um mamìfero, usos de uma combinação de cci-779 e rituximab e de uma combinação de um inibidor de mtor e rituximab, produtos contendo cci-779 e rituximab e um inibidor mtor e rituximab, embalagem farmacêutica, e, composição farmacêutica
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
DE60318013D1 (de) N-oxid von n-phenyl-2-pyrimidinaminderivaten
ATE506953T1 (de) 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
ATE369372T1 (de) 42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
ATE427116T1 (de) Behandlung von bakteriellen infektionen
ATE393221T1 (de) Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen
ATE307625T1 (de) Wirkstoffabgabesysteme zur behandlung von gefässerkrankungen
BR0315437A (pt) Composição para o tratamento dos cabelos, usos da mesma e método para o tratamento dos cabelos
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
DK1140198T3 (da) Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
WO2004009773A3 (en) Methods and compositions for activating or inhibiting vegf-d and vegf-c
DE60317098D1 (de) Carbostyril-derivate mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von gemütskrankheiten
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
DE60219658D1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
BR0014372A (pt) Derivados de 5-hidroxissapogenina com atividade antidemência
ITMI20041295A1 (it) Composizioni farmaceutiche antimicrobiche orali
EP2093297A3 (de) Wirkstoffe zur Behandlung oder Vorbeugung einer allergischen Störung
DE602004025689D1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren

Legal Events

Date Code Title Description
8332 No legal effect for de